> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Immunovant Seeks Aggressive Arthritis Approval Path While Guarding Its Antibody Findings
- URL: https://www.bullished.co/immunovant-seeks-aggressive-arthritis-approval-path-while-guarding-its-antibody-findings-ba0da810/
- Published: 2026-11-09T14:26:14.000Z
- Updated: 2026-11-09T14:26:14.000Z
- Description: Higher-dose patients maintained arthritis responses, but FDA discussions will determine the next trial's design.
- Author: Matteo Parrino
- Tags: Earnings, IMVT, Industry: Healthcare

[Immunovant](https://www.bullished.co/tag/imvt/), which develops experimental antibody medicines for autoimmune diseases, wants to pursue an aggressive rheumatoid arthritis approval strategy while keeping antibody measurements from competitors, Roivant Sciences Chief Executive Officer Matt Gline said on the company's earnings call Monday. The program began with [170 participants receiving](https://www.globenewswire.com/news-release/2026/11/09/3398263/0/en/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended-september-30-2026.html?ref=bullished.co) the higher dose for 16 weeks, according to Immunovant's release; management now wants to focus development on patients who have exhausted multiple treatments.

## 600 Milligrams Preserved The Benefit

Patients who responded to initial treatment could enter a 12-week comparison that kept them on 600 milligrams, lowered their dose to 300 milligrams or switched them to placebo. Of the 118 patients randomized, 117 entered the efficacy analysis.

At week 28, 92.5% of patients on 600 milligrams retained an ACR20 response, the trial's measure of at least 20% improvement in arthritis symptoms, versus about 75% on placebo. The higher dose met the study's main goal. For the deeper ACR50 response measure, rates were 80% on 600 milligrams and 56% on placebo; Gline also reported separation on ACR70, without nominal statistical significance.

The lower dose looked similar to placebo. "300 milligrams was not enough to preserve the response," Gline said. He argued that deeper suppression of antibodies explained the sustained benefit at the higher dose.

The selection of responders limits what this comparison establishes: it tested persistence of an existing benefit, rather than the likelihood that previously untreated patients would respond. Gline said patients who had previously tried JAK inhibitors performed similarly to the overall population, and reported no new safety signals, with adverse-event rates comparable to placebo.

## Antibody Measurements Stay Under Wraps

An analyst asked for antibody-reduction measurements and whether patients with deeper reductions had better outcomes. Gline said management was deliberately withholding those findings because competitors closely follow its research. He described the analyses as consistent with the view that greater antibody reduction produces better outcomes.

Immunovant's focus is imeroprubart, also called IMVT-1402\. The experimental medicine targets a protein that keeps antibodies from breaking down, aiming to reduce harmful antibodies that attack the body's tissues. Its studies use an injectable formulation delivered by autoinjector.

The company's research covers endocrinology, neurology, rheumatology and dermatology. Its ongoing studies span Graves' disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren's disease and cutaneous lupus.

Gline said enrollment in Graves' disease had been strong and expected to provide more precise timing information relatively soon. He identified Graves' and myasthenia gravis data among the updates expected in 2027.

## FDA Sets The Arthritis Route

Gline estimated about 85,000 U.S. patients fit the difficult-to-treat arthritis population. Participants had failed conventional treatment and at least two mechanisms of advanced therapy. He said reaching these patients takes priority over expanding immediately into other arthritis populations or diseases.

Asked by a TD Cowen analyst whether a single late-stage trial could support approval and what its endpoint would be, Gline said, "we don't know on either of those questions for sure." He expects a conventional randomized controlled trial rather than another withdrawal study, but said FDA discussions will determine its particulars. Management does not intend a significant change in enrollment criteria, subject to those discussions.

The Sjögren's program faces a different decision. Gline told a Citi analyst that management probably would not advance beyond its ongoing mid-stage study. He cited competitors' experience, including a failed futility analysis involving 500 patients, as a reason not to expand the study or add a late-stage trial now. Immunovant intends to finish the study and would reconsider if it produces surprising results.

Gline expects to update investors on the arthritis trial plans later this year or early next year, once FDA discussions are finished.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Immunovant Provides Corporate Updates and Reports Financial](https://www.globenewswire.com/news-release/2026/11/09/3398263/0/en/immunovant-provides-corporate-updates-and-reports-financial-results-for-the-quarter-ended-september-30-2026.html?ref=bullished.co) — globenewswire.com
- [Roivant Reports Financial Results for the Second Quarter](https://www.globenewswire.com/news-release/2026/11/09/3398229/34323/en/roivant-reports-financial-results-for-the-second-quarter-ended-september-30-2026-and-provides-business-update.html?ref=bullished.co) — globenewswire.com

### More on Immunovant

- [Immunovant Posts $97.2 Million Quarterly Loss — Arthritis Drug Meets Main Trial Goal](https://www.bullished.co/immunovant-posts-97-2-million-quarterly-loss-arthritis-drug-meets-main-trial-goal-1edab127/)

[All Immunovant (IMVT) coverage →](https://www.bullished.co/tag/imvt/)